Expanding access to Psychedelic-Assisted Psychotherapy
Open for applications
Expanding access to Psychedelic-Assisted Psychotherapy
21-100 employees
Open for applications
21-100 employees
To empower licensed mental health professionals to incorporate Ketamine-Assisted Psychotherapy (KAP) in their practice safely and effectively.
Jump to section
To empower licensed mental health professionals to incorporate Ketamine-Assisted Psychotherapy (KAP) in their practice safely and effectively.
Few candidates hear
back within 2 weeks
70% employee growth in 12 months
With mental health awareness on the rise, the demand for new methods of treatment has increased dramatically. Journey Clinical is meeting this demand by improving access to Psychedelic-Assisted Psychotherapy.
Journey Clinical's main focus is Ketamine Assisted Psychotherapy, which has become increasingly sought after in recent years. KAP has a number of applications, including treatment for anxiety, depression, and PTSD.
Journey Clinical's main challenge will be competing with similar providers, such as Field Trip and Compass Pathways, though its laser focus on KAP should help it stand out. The company has also raised significant funding that will support in scaling its offerings across the US.
Kirsty
Company Specialist
Jan 2023
$8.5m
SERIES A
Sep 2021
$3m
SEED
This company has top investors
Founders
Jonathan Sabbagh
(CEO)Was Head of Geneva Office at Columbia Threadneedle Investments. Was Managing Director and Founder of Gottex Brokers SA.
Myriam Barthes
(COO)Previously worked as a Manager at EY, and was an AI Impact Strategist and Client Partner at SparkBeyond.
Office
Jobs (3)
People, HR, Recruitment
Sales & Account Management